Understanding the causes of early pulmonary fibrosis
Official title: Disease Mechanisms of Early Pulmonary Fibrosis
Funded at University of Michigan at Ann Arbor · NIH-10846182 · Data updated 2026-11-12
This study is looking for new ways to help people at risk of progressive pulmonary fibrosis by understanding how lung injuries can lead to the disease, so it can find ways to prevent symptoms before they start.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 17, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $2,857,933 |
| NIH project number | 1P01HL172729-01 |
| Project ID | NIH-10846182 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include asymptomatic individuals with a family history of pulmonary fibrosis.
✕Less likely to help
Patients who already exhibit symptoms of pulmonary fibrosis may not benefit from this research.
What this research studies
This research aims to develop new therapies to significantly reduce the health impacts of progressive pulmonary fibrosis (PF). It focuses on understanding PF as a result of long-term lung injury rather than just a final stage of the disease. By studying genetic, metabolic, and environmental factors that contribute to the early stages of PF, the research seeks to identify ways to prevent the onset of symptoms. The program will utilize data from a cohort of asymptomatic relatives of patients with familial PF to inform its findings.
Why it matters
Potential benefit: If successful, this research could lead to innovative strategies for preventing pulmonary fibrosis before it becomes symptomatic.
How similar studies have gone: Previous research has shown promise in understanding disease mechanisms in similar conditions, suggesting potential for success in this novel approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Blackwell, Timothy S. — University of Michigan at Ann Arbor
- Study coordinator: Blackwell, Timothy S.
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.